

Editorials

Editorial.

Kenneth C. Anderson 1

Another Negative Chemoprevention Trial: What Can We Learn?

□□ *Commentary on Sabichi et al., p. 224*

Frank L. Meyskens, Jr. 2

Perspectives

The Immunogenicity of the hTERT540-548 Peptide in Cancer.

Lynn Wenandy, Rikke Bæk Sørensen, Lisa Sengeløv, Inge Marie Svane, Per thor Straten,

and Mads Hald Andersen 4

Reviews

Can Inhibiting Dihydropyrimidine Dehydrogenase Limit Hand-Foot Syndrome Caused by Fluoropyrimidines?

Jane L. Yen-Revollo, Richard M. Goldberg, and Howard L. McLeod 8

Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems.

Brian R.J. Healey Bird and Sandra M. Swain 14

Human Cancer Biology

Two Distinct Local Relapse Subtypes in Invasive Breast Cancer: Effect on their Prognostic Impact.

Patrizia Casalini, Maria Luisa Carcangiu, Raija Tammi, Päivi Auvinen, Veli-Matti Kosma, Pinuccia Valagussa, Marco Greco, Andrea Balsari, Sylvie Ménard, and Elda Tagliabue 25

Contents of Endometriotic Cysts, Especially the High Concentration of Free Iron, Are a Possible Cause of Carcinogenesis in the Cysts through the Iron-Induced Persistent Oxidative Stress.

Ken Yamaguchi, Masaki Mandai, Shinya Toyokuni, Junzo Hamanishi, Toshihiro Higuchi, Kenji Takakura, and Shingo Fujii 32

Loss and Reduction of Fus1 Protein Expression is a Frequent Phenomenon in the Pathogenesis of Lung Cancer.

Ludmila Prudkin, Carmen Behrens, Diane D. Liu, Xian Zhou, Natalie C. Ozburn, B. Nebiyu Bekele, John D. Minna, Cesar Moran, Jack A. Roth, Lin Ji, and Ignacio I. Wistuba 41

Aberrant Crypt Foci as Precursors of the Dysplasia-Carcinoma Sequence in Patients with Ulcerative Colitis.

Takehiro Kukitsu, Tetsuji Takayama, Koji Miyanishi, Atsushi Nobuoka, Shinichi Katsuki, Yasushi Sato, Rishu Takimoto, Takuya Matsunaga, Junji Kato, Tomoko Sonoda, Sumio Sakamaki, and Yoshiro Niitsu 48

WNT5A Exhibits Tumor-Suppressive Activity through Antagonizing the Wnt/ β -Catenin Signaling, and Is Frequently Methylated in Colorectal Cancer.

Jianming Ying, Hongyu Li, Jun Yu, Ka Man Ng, Fan Fong Poon, Sze Chuen Cesar Wong, Anthony T.C. Chan, Joseph J.Y. Sung, and Qian Tao 55

Imaging, Diagnosis, Prognosis

Vascular Endothelial Growth Factor Gene Polymorphisms Associated with Prognosis for Patients with Colorectal Cancer.

Jong Gwang Kim, Yee Soo Chae, Sang Kyun Sohn, Yoon Young Cho, Joon Ho Moon, Jae Yong Park, Seoung Woo Jeon, In Taek Lee, Gyu Seog Choi, and Soo-Han Jun 62

Prognostic Significance of Cyclooxygenase-2 Overexpression in Glottic Cancer.

Melanie K. Sackett, Isabelle Bairati, François Meyer, Édith Jobin, Sébastien Lussier, André Fortin, Michel Gélinas, Abdenour Nabid, François Brochet, and Bernard Têtu 67

Identification of Matrix Metalloproteinase 11 as a Predictive Tumor Marker in Serum Based on Gene Expression Profiling. Yan-Hong Yang, Hua Deng, Wen-Mei Li, Qing-Yun Zhang, Xiao-Ting Hu, Bai Xiao, Hai-Hong Zhu, Pai-Li Geng, and You-Yong Lu	74
Impact of E2F-1 Expression on Clinical Outcome of Gastric Adenocarcinoma Patients with Adjuvant Chemoradiation Therapy. Jeeyun Lee, Cheol Keun Park, Joon Oh Park, Taekyu Lim, Young Suk Park, Ho Yeong Lim, Inkyoung Lee, Tae Sung Sohn, Jae Hyung Noh, Jin Seok Heo, Sung Kim, Do Hoon Lim, Kyoung-Mee Kim, and Won Ki Kang.....	82
Both Germ Line and Somatic Genetics of the p53 Pathway Affect Ovarian Cancer Incidence and Survival. Frank Bartel, Juliane Jung, Anja Böhnke, Elise Gradhand, Katharina Zeng, Christoph Thomssen, and Steffen Hauptmann	89
Evaluation of Promoter Hypermethylation Detection in Body Fluids as a Screening/Diagnosis Tool for Head and Neck Squamous Cell Carcinoma. André Lopes Carvalho, Carmen Jeronimo, Michael M. Kim, Rui Henrique, Zhe Zhang, Mohammad O. Hoque, Steve Chang, Mariana Brait, Chetan S. Nayak, Wei-Wen Jiang, Quia Claybourne, Yutaka Tokumaru, Juna Lee, David Goldenberg, Elizabeth Garrett-Mayer, Steven Goodman, Chul-so Moon, Wayne Koch, William H. Westra, David Sidransky, and Joseph A. Califano.....	97
How Large a Training Set is Needed to Develop a Classifier for Microarray Data? Kevin K. Dobbin, Yingdong Zhao, and Richard M. Simon.....	108
Integrative Genomic Analysis of Aneuploidy in Uveal Melanoma. Justis P. Ehlers, Lori Worley, Michael D. Onken, and J. William Harbour	115
Stem Cell Marker CD133 Affects Clinical Outcome in Glioma Patients. Felix Zeppernick, Rezvan Ahmadi, Benito Campos, Christine Dictus, Burkhard M. Helmke, Natalia Becker, Peter Lichter, Andreas Unterberg, Bernhard Radlwimmer, and Christel C. Herold-Mende	123
Axl and Growth Arrest-Specific Gene 6 Are Frequently Overexpressed in Human Gliomas and Predict Poor Prognosis in Patients with Glioblastoma Multiforme. Markus Hutterer, Pjotr Knyazev, Ariane Abate, Markus Reschke, Hans Maier, Nadia Stefanova, Tatjana Knyazeva, Verena Barbieri, Markus Reindl, Armin Muigg, Herwig Kostron, Guenther Stockhammer, and Axel Ullrich	130
Identification of Patients with (Atypical) <i>MUTYH</i>-Associated Polyposis by <i>KRAS2</i> c.34G > T Prescreening Followed by <i>MUTYH</i> Hotspot Analysis in Formalin-Fixed Paraffin-Embedded Tissue. Marjo van Puijenbroek, Maartje Nielsen, Carli M.J. Tops, Hans Halfwerk, Hans F.A. Vasen, Marjan M. Weiss, Tom van Wezel, Frederik J. Hes, and Hans Morreau	139
Node-Negative Colorectal Cancer at High Risk of Distant Metastasis Identified by Combined Analysis of Lymph Node Status, Vascular Invasion, and Raf-1 Kinase Inhibitor Protein Expression. Inti Zlobec, Kristi Baker, Parham Minoo, Jeremy R. Jass, Luigi Terracciano, and Alessandro Lugli	143

Cancer Therapy: Clinical

Bronchopulmonary Carcinoid: Phenotype and Long-term Outcome in a Single-Institution Series of Italian Patients. Massimo Rugge, Matteo Fassan, Roberto Clemente, Giovanna Rizzardi, Luciano Giacomelli, Gianmaria Pennelli, Claudia Mescoli, Daniela Segat, and Federico Rea	149
Fludarabine, Cyclophosphamide, and Mitoxantrone as Initial Therapy of Chronic Lymphocytic Leukemia: High Response Rate and Disease Eradication. Francesc Bosch, Ana Ferrer, Neus Villamor, Marcos González, Javier Briones, Eva González-Barca, Eugenia Abella, Santiago Gardella, Lourdes Escoda, Elena Pérez-Ceballos, Antoni Asensi, Ma José Sayas, Llorenç Font, Albert Altés, Ana Muntañola, Paola Bertazzoni, María Rozman, Marta Aymerich, Eva Giné, and Emili Montserrat.....	155
Radiotherapy in Lung Adenocarcinoma with Brain Metastases: Effects of Activating Epidermal Growth Factor Receptor Mutations on Clinical Response. Chien-Hung Gow, Chun-Ru Chien, Yih-Leong Chang, Yueh-Hsia Chiu, Sung-Hsin Kuo, Jin-Yuan Shih, Yeun-Chung Chang, Chong-Jen Yu, Chih-Hsin Yang, and Pan-Chyr Yang.....	162

Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity. Gemma G. Kenter, Marij J.P. Welters, A. Rob P.M. Valentijn, Margriet J.G. Löwik, Dorien M.A. Berends-van der Meer, Annelies P.G. Vloon, Jan W. Drijfhout, Amon R. Wafelman, Jaap Oostendorp, Gert Jan Fleuren, Rienk Offringa, Sjoerd H. van der Burg, and Cornelis J.M. Melief.....	169
Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine. Marij J.P. Welters, Gemma G. Kenter, Sytse J. Piersma, Annelies P.G. Vloon, Margriet J.G. Löwik, Dorien M.A. Berends-van der Meer, Jan W. Drijfhout, A. Rob P.M. Valentijn, Amon R. Wafelman, Jaap Oostendorp, Gert Jan Fleuren, Rienk Offringa, Cornelis J.M. Melief, and Sjoerd H. van der Burg.....	178
Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin. David S. Schrupp, Maria R. Fischette, Dao M. Nguyen, Ming Zhao, Xinmin Li, Tricia F. Kunst, Ana Hancox, Julie A. Hong, G. Aaron Chen, Evgeny Kruchin, John J. Wright, Douglas R. Rosing, Alex Sparreboom, William D. Figg, and Seth M. Steinberg.....	188
Interleukin-13 Receptor α2, EphA2, and Fos-Related Antigen 1 as Molecular Denominators of High-Grade Astrocytomas and Specific Targets for Combinatorial Therapy. Jill Wykosky, Denise M. Gibo, Constance Stanton, and Waldemar Debinski.....	199
A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer. William L. Dahut, Charity Scripture, Edwin Posadas, Lokesh Jain, James L. Gulley, Philip M. Arlen, John J. Wright, Yunkai Yu, Liang Cao, Seth M. Steinberg, Jeanny B. Aragon-Ching, Jürgen Venitz, Elizabeth Jones, Clara C. Chen, and William D. Figg.....	209
Phase I Pharmacokinetic/Pharmacodynamic Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Combination with Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in First-Line Treatment of Patients with Metastatic Colorectal Cancer. Gunnar Folprecht, Josep Tabernero, Claus-Henning Köhne, Charles Zacharchuk, Luis Paz-Ares, Federico Rojo, Susan Quinn, Esther Casado, Ramon Salazar, Richat Abbas, Chantal Lejeune, Irene Marimón, Jordi Andreu, Ulrike Ubbelohde, Hernan Cortes-Funes, and Jose Baselga.....	215
Phase III Prevention Trial of Fenretinide in Patients with Resected Non-Muscle-Invasive Bladder Cancer. Anita L. Sabichi, Seth P. Lerner, E. Neely Atkinson, H. Barton Grossman, Nancy P. Caraway, Colin P. Dinney, David F. Penson, Surena Matin, Ashish Kamat, Louis L. Pisters, Daniel W. Lin, Ruth L. Katz, Dean E. Brenner, George P. Hemstreet III, Mary Wargo, Archie Bleyer, William H. Sanders, John L. Clifford, Howard L. Parnes, and Scott M. Lippman.....	224

Cancer Therapy: Preclinical

The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor AZD6244 (ARRY-142886) Induces Growth Arrest in Melanoma Cells and Tumor Regression When Combined with Docetaxel. Nikolas K. Haass, Katrin Sproesser, Thiennga K. Nguyen, Rooha Contractor, C. Angelica Medina, Katherine L. Nathanson, Meenhard Herlyn, and Keiran S.M. Smalley.....	230
SNX2112, a Synthetic Heat Shock Protein 90 Inhibitor, Has Potent Antitumor Activity against HER Kinase-Dependent Cancers. Sarat Chandralapaty, Ayana Sawai, Qing Ye, Anisa Scott, Melanie Silinski, Ken Huang, Pat Fadden, Jeff Partdrige, Steven Hall, Paul Steed, Larry Norton, Neal Rosen, and David B. Solit.....	240
Blocking Vascular Endothelial Growth Factor-A Inhibits the Growth of Pituitary Adenomas and Lowers Serum Prolactin Level in a Mouse Model of Multiple Endocrine Neoplasia Type 1. Nina Korsisaari, Jed Ross, Xiumin Wu, Marcin Kowanzetz, Navneet Pal, Linda Hall, Jeffrey Eastham-Anderson, William F. Forrest, Nicholas Van Bruggen, Franklin V. Peale, and Napoleone Ferrara.....	249
Cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneous Tumors following Intravenous Delivery of Reovirus. Jian Qiao, Hongxun Wang, Timothy Kottke, Christine White, Katie Twigger, Rosa Maria Diaz, Jill Thompson, Peter Selby, Johann de Bono, Alan Melcher, Hardev Pandha, Matt Coffey, Richard Vile, and Kevin Harrington.....	259

Combining Agents that Target the Tumor Microenvironment Improves the Efficacy of Anticancer Therapy. Joseph A. Blansfield, Diana Caragacianu, H. Richard Alexander III, Michael A. Tangrea, Shane Y. Morita, Dominique Lorang, Peter Schafer, George Muller, David Stirling, Richard E. Royal, and Steven K. Libutti.....	270
Antitumor Effects of Systemically Delivered Adenovirus Harboring <i>Trans</i>-Splicing Ribozyme in Intrahepatic Colon Cancer Mouse Model. Jin-Sook Jeong, Seong-Wook Lee, Seung-Hee Hong, Yoon-Jong Lee, Haeng-Im Jung, Kyung-Sook Cho, Hye-Hyun Seo, Sang-Jin Lee, Sohee Park, Min-Sun Song, Chang-Min Kim, and In-Hoo Kim	281
Prostate-Restricted Replicative Adenovirus Expressing Human Endostatin-Angiostatin Fusion Gene Exhibiting Dramatic Antitumor Efficacy. Xiong Li, You-Hong Liu, Sang-Jin Lee, Thomas A. Gardner, Meei-Huey Jeng, and Chinghai Kao	291
Oral Silibinin Inhibits <i>In vivo</i> Human Bladder Tumor Xenograft Growth Involving Down-Regulation of Survivin. Rana P. Singh, Alpna Tyagi, Girish Sharma, Sarumathi Mohan, and Rajesh Agarwal	300
Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other Alkylating Agents. Lorenzo M. Leoni, Brandi Bailey, Jack Reifert, Heather H. Bendall, Robert W. Zeller, Jacques Corbeil, Gary Elliott, and Christina C. Niemeyer.....	309
Using Pharmacokinetic and Pharmacodynamic Modeling and Simulation to Evaluate Importance of Schedule in Topotecan Therapy for Pediatric Neuroblastoma. John C. Panetta, Paula Schaiquevich, Victor M. Santana, and Clinton F. Stewart	318

Correction


Correction: Article on Human Glioma Cell Growth.....	326
--	-----

Acknowledgment to Reviewers

Acknowledgment to Reviewers.....	327
----------------------------------	-----

About the Cover

A histologic section of a MEN 1 pituitary tumor following administration of an anti-VEGF-A antibody. Treatment with anti-VEGF-A resulted in a 3.7-fold inhibition of the pituitary tumor growth and increased mean tumor doubling-free survival compared with mice treated with a control antibody. Vessel density was reduced by anti-VEGF-A treatment to 46% that of control IgG-treated tumors. For further details, please see the article by Korsisaari and associates on page 249 of this issue.



Clinical Cancer Research

14 (1)

Clin Cancer Res 2008;14:1-336.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/14/1>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/14/1>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.